zurück Home | Primärtherapie des Mamma - Karzinoms | |||
allgemeines |
||||
Diagnose-Sicherung |
||||
Ausbreitungs-Diagnostik |
||||
Sondersituationen |
||||
operative Therapie | ||||
postoperative Bestrahlung |
||||
adjuvante systemische Therapie |
||||
brusterhaltende Therapie | ||||
HER2 + Rezeptor + |
ALTERNATIVE-Studie | Lapatinib + Trastzumab + Aromatasehemmer (doppelte Her2-Blockade) besser als Trastzumab + Aromatasehemmer oder Lapatinib + Aromatasehemmer | ||
Quellen |
1.) Early Breast Cancer Trialists' Collaborative Group (EBCTCG)Darby S, McGale P, et al.: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707–1716 2.) Johnston S R D, et al.: Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor – Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol 2020;39:79-89 DOI org/10.1200/JCO.20.01894 | |||
Teil von |
Therapie des Mamma - Karzinoms | Mamma - Karzinom | ||
Impressum Zuletzt geändert am 31.01.2020 11:56